These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Cytoskeleton actin-binding proteins in clinical behavior of pituitary tumors. Mantovani G; Treppiedi D; Giardino E; Catalano R; Mangili F; Vercesi P; Arosio M; Spada A; Peverelli E Endocr Relat Cancer; 2019 Feb; 26(2):R95-R108. PubMed ID: 30589642 [TBL] [Abstract][Full Text] [Related]
27. Pituitary tumors. Melmed S Endocrinol Metab Clin North Am; 2015 Mar; 44(1):1-9. PubMed ID: 25732636 [TBL] [Abstract][Full Text] [Related]
28. The immunophilin-like protein XAP2 is a negative regulator of estrogen signaling through interaction with estrogen receptor α. Cai W; Kramarova TV; Berg P; Korbonits M; Pongratz I PLoS One; 2011; 6(10):e25201. PubMed ID: 21984905 [TBL] [Abstract][Full Text] [Related]
29. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes. Cristina C; Díaz-Torga GS; Goya RG; Kakar SS; Perez-Millán MI; Passos VQ; Giannella-Neto D; Bronstein MD; Becu-Villalobos D Mol Cancer; 2007 Jan; 6():4. PubMed ID: 17222350 [TBL] [Abstract][Full Text] [Related]
30. Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Heaney AP; Fernando M; Yong WH; Melmed S Nat Med; 2002 Nov; 8(11):1281-7. PubMed ID: 12379847 [TBL] [Abstract][Full Text] [Related]
31. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality? Tahmatzopoulos A; Kyprianou N Prostate; 2004 Apr; 59(1):91-100. PubMed ID: 14991869 [TBL] [Abstract][Full Text] [Related]
33. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects. Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843 [TBL] [Abstract][Full Text] [Related]